# Identifying COVID-19 Confirmed Patients at Elevated Risk for Mortality and Need of Mechanical Ventilation Using a Novel Criteria for Hyperinflammatory Syndrome: A Retrospective Cohort, Single-center, Validation Study

Jayvee Rho-An D. Descalsota, MD,[1] Abdul Walli R. Cana, MD,[1] Inofel I. Chin, MD[2] and Jessie F. Orcasitas, MD[3]

*[1]Department of Internal Medicine, Southern Philippines Medical Center, Davao City*
*[2]Section of Infectious Diseases, Department of Internal Medicine, Southern Philippines Medical Center, Davao City*
*[3]Section of Pulmonology, Department of Internal Medicine, Southern Philippines Medical Center, Davao City*

## ABSTRACT

**Background and Objectives.** A mounting evidence links dysregulated immune response to cases of fatal pneumonia seen in COVID-19 infection. We aimed to validate the COVID-19-associated Hyperinflammatory Syndrome (cHIS) score, a novel clinical tool devised to identify those at risk for adverse outcomes, in a local population and investigate the relationship of cHIS score taken at admission and the risk of mortality and the need of mechanical ventilation.

**Methods.** This retrospective cohort study analyzed the sociodemographic, clinical, and laboratory data of 1,881 COVID-19 patients admitted at a tertiary hospital in Davao City, Philippines from January to December 2021. We calculated the cHIS score, composed of six clinical and laboratory criteria from admission, and used multivariate logistic regression to determine the risk of mortality and need of mechanical ventilation.

**Results.** The cHIS score taken at admission, regardless of cut-off value, was a significant predictor of mortality (OR 0.979 [99% CI 0.894-1.064]) and need of mechanical ventilation (OR 0.586 [99% CI 0.4975-0.6745]). Using the Youden Index, a cut-off cHIS score of 3 or more was a better predictor of mortality (sensitivity, 88.59%; specificity, 71.72%), and a cut-off score of 2 or more was a better predictor of need of mechanical ventilation (sensitivity, 84.02%; specificity, 70.82%) than other cut-off cHIS scores.

**Conclusion.** Among COVID-19 patients, the cHIS score at admission correlated with the risk of mortality and the need of mechanical ventilation. Cutoff scores of 3 and 2 had the optimal sensitivities and specificities to predict the risk of mortality and the need of mechanical ventilation, respectively.

*Keywords: COVID-19, inflammation, mortality, mechanical ventilation, cytokine storm*

# INTRODUCTION

## Background of the Study

As of January 2023, the pandemic sparked by the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) has claimed over 6.7 million lives worldwide, with an estimated 664 million people having already been infected. Since the start of the pandemic, the Philippines has logged 65,865 deaths, with at least 4.073 million confirmed cases and counting.[1]

The SARS-CoV-2, which was first documented in Wuhan, China in December 2019, is a novel enveloped RNA betacoronavirus that causes a systemic illness marked by fever, cough, and dyspnea, with predilection toward severity among the elderly and those with multiple comorbidities. As cellular targets of SARS-CoV-2 via the angiotensin-converting enzyme 2 (ACE2) receptor, macrophages and monocytes were shown in early studies to be aberrantly activated, leading to downstream immune dysregulation.[2]

Most of the infected patients were either asymptomatic or have mild presentations, but a significant number of these individuals would succumb to rapid clinical deterioration characterized by maladaptive elaboration of cytokines.[3,4] Interferon gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) cause flu-like symptoms such as fever and chills, myalgias, dizziness, and fatigue, while interleukin-6 leads to vasculopathy, complement activation, and abnormal coagulation cascade, leading to disseminated intravascular coagulation (DIC).[5,6] In addition, these cytokines are linked to cardiomyopathy, lung injury, vascular leakage, and acute-phase protein synthesis.[5] Endothelial dysfunction from cytokine storm had previously been linked to coagulopathy, capillary leakage, and hypotension.[7]

An analysis of plasma cytokine levels in 41 COVID-19 patients in China in the early days of the outbreak revealed elevated levels of IFN-γ, TNF-α, interleukins, and other inflammatory cytokines. Among these patients, all developed pneumonia, a third received intensive care, and six expired.[8]

Virus-induced hyperinflammatory response plays a crucial role in the fatal pneumonia observed among COVID-19 patients. This hyperinflammatory state has been likened to that seen in secondary Hemophagocytic Lympho-histiocytosis (HLH), Macrophage Activation Syndrome (MAS), and Cytokine Release Syndrome (CRS).[9-11]

In December 2020, Webb et al. proposed the term COVID-19-associated hyperinflammatory syndrome (cHIS) to describe this immunologic disarray found among critically ill COVID-19 patients. An additive six-point scoring system called cHIS criteria, a clinical tool to identify those patients at risk for adverse outcomes, was developed. The variables for this criterion were derived from the clinical and laboratory features of conserved physiologic pathway of unchecked macrophage activation and cytokine production found in secondary HLH, MAS, and CRS.[12] The six components of this scoring system were *fever*, *macrophage activation*, *hematologic dysfunction*, *coagulopathy*, *hepatic injury*, and *cytokinemia*.[12]

An admission cHIS score of two or more was found to be significantly associated with in-hospital mortality or mechanical ventilation. The criteria appeared to have prognostic utility and might be useful for selection of patients for clinical trials and immunomodulatory therapy. Although this scoring system has been validated among patients in the Inter-mountain Prospective Observational COVID-19 (IPOC) registry in Salt Lake City, Utah, USA, further validity tests in large external cohorts are needed to enhance its applicability.[12]

In one of the first external validations of cHIS score among 370 critically ill COVID-19 confirmed patients in Turkey, an admission cHIS score of three or more was associated with mortality and invasive mechanical ventilation.[13] In another retrospective study among 57 COVID-19 confirmed patients with comorbid rheumatic diseases in USA, a cHIS score of 2 or more had higher odds of admission to intensive care, mechanical ventilation, and in-hospital mortality than patients with a peak cHIS of less than 2.[14]

Currently, there is no evidence-based system that is used to stratify patients according to their risk of mortality and need of mechanical ventilation. With the mounting evidence linking dysregulated immune response and clinical deterioration, a stratification system based on inflammatory markers, such as the cHIS score, should be pursued for local validation and application.

## Significance of the Study

A number of COVID-19 patients follow an initially benign clinical course, only to rapidly deteriorate, requiring intubation and mechanical ventilation. Most studies indicate that these patients are in a hyperinflammatory state, marked by excessive production of cytokines that lead to end-organ damage.[2-4,12] This subset of patients needs to be identified early using a valid criteria that employs readily available parameters.

Stratifying patients as mild, moderate, severe, and critical based on clinical and radiologic findings has been the local practice since the start of the pandemic, which is based on the WHO Clinical Management of COVID-19 Interim Guidance.[15] However, several patients have been re-stratified to higher levels of severity due to clinical deterioration that could have been predicted by better tools based on the elevated inflammatory markers at the time of admission.

The locally used "*Rule of 6*" is theoretically based on disordered immune response. Composed of universal values of Ferritin >60 ug/L, CRP >60 mg/ml, and LDH >600 ug/L in the first 48 hours of admission, it is convenient to use but is arbitrary at best and is not rooted on evidence-based studies.

The novel cHIS criteria, developed by Webb et. al, is a theoretically robust and validated criteria that can be applied locally. If locally validated, this criteria can help triage patients to the appropriate level of care at the time of admission. Limited resources and manpower can be properly allocated to the patients. Physicians and allied health workers can then monitor their patients better and institute more timely interventions, potentially resulting in better patient outcomes.

## OBJECTIVES

### General Objective

1. To correlate the admission cHIS score among COVID-19 confirmed patients with their risk of mortality and need of mechanical ventilation

### Specific Objectives

1. To present the sociodemographic profile (i.e.; age, sex, body mass index, COVID-19 severity, and co-morbidities) of COVID-19 confirmed patients admitted at Southern Philippines Medical Center from January to December 2021
2. To establish the relationship between the patient's admitting cHIS score and the risk of mortality and need of mechanical ventilation
3. To determine the optimal cut-off value of cHIS score, including its sensitivity and specificity, as a predictor of mortality and need of mechanical ventilation

## MATERIALS AND METHODS

### Research Design, Setting, and Participants

This research was a retrospective cohort study among COVID-19 confirmed patients admitted at Southern Philippines Medical Center, a tertiary COVID-19 end referral center in Davao City, Philippines, from January 1 to December 31, 2021, meeting the following inclusion criteria:

### Inclusion Criteria

1. Patients aged 19 and above with SARS-CoV-2 infection as confirmed by positive Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) done at SPMC or other Department of Health (DOH)-accredited laboratory in Davao City who were admitted, examined, worked-up and treated at SPMC from January 1 to December 31, 2021
2. Patients triaged and admitted either from the Main ER or Isolation ER of SPMC
3. Patients initially admitted at or transferred to a Temporary Treatment and Monitoring Facility (TTMF) but were referred back to Isolation ER for workup due to clinical deterioration
4. May be asymptomatic, mild, moderate, severe, or critical. Asymptomatic patients were classified under mild
5. Must be registered on SPMC Segworks Hospital Information System (SegHIS) Database

### Exclusion Criteria

1. COVID-19 Suspects with pending RT-PCR results
2. COVID-19 Probable who were already being managed as COVID-19 Confirmed with negative RT-PCR confirmation (at least two samples)
3. COVID-19 Probable by virtue of positive RAgT test kits only

4. COVID-19 Confirmed persistently positive patients with positive SARS-CoV-2 IgG and those who were cleared by Infectious Disease Consultant as Recovered cases
5. COVID-19 Confirmed patients admitted and who had completed quarantine at a TTMF
6. COVID-19 Confirmed patients with medical or surgical problems initially admitted as non-COVID with negative RT-PCR, but were later found to have positive swabs on repeat in-patient RT-PCR at the wards (hospital-acquired COVID-19)
7. COVID-19 Confirmed but Recovered patients with ongoing medical problems and still admitted at the non-COVID wards
8. COVID-19 Confirmed End Stage Renal Disease (ESRD) patients admitted at a TTMF who were only referred to the Isolation Facility for their scheduled hemodialysis sessions
9. Adult patients who died at the outset and whose COVID-19 confirmed status was only discerned post-mortem
10. COVID-19 Confirmed patients with incomplete data and parameters for cHIS scoring

### Sample Size and Sampling Procedure

The required sample size was computed via power analysis under the z tests family under logistic regression. The assumed null sensitivity of risk of mortality at 0.15 was taken from Abad et al. from a tertiary hospital in the Philippines.[16] A conservative alternative sensitivity of 0.20 was assumed, slightly below the studies of Salva et al. and slightly above Salamat et al. both in the Philippine context.[17,18] This resulted to an expected odds ratio of 1.51. The remaining parameter, α power was set at accepted levels of 0.05 and 0.95. Utilizing the statistical software G*Power 3, the sample size was determined to be 607 with an actual power of 0.95.[19] The authors utilized convenience sampling, enumerating all adult COVID-19 confirmed patients that met the inclusion and exclusion criteria covering the running census from January 2021 to December 2021.

### Data Gathering

The patients' data were retrieved from Southern Philippines Medical Center (SPMC) COVID-19 Census and SPMC Segworks Hospital Information System (SegHIS) Database. The subjects' identifiable information were designated by alphanumeric code to provide anonymity. The subjects' data for use were: age, sex, body mass index, severity, comorbidities, incidence of mechanical ventilation, in-hospital all-cause mortality, and laboratory values.[20,21]

Direct communication was done with the originator of the cHIS scoring system, Dr. Brandon J. Webb from the Intermountain Medical Center in Salt Lake City, Utah, USA through electronic exchanges via e-mail. Permission was granted by the said author for the request to apply the six-point criteria to this local study.

COVID-19 Hyperinflammatory Syndrome (cHIS) was scored additively using a six-point scale as operationally defined in Appendix A.

## Data Analysis

Descriptive statistics was used to summarize and report the sociodemographic profile of the subjects. Hot deck imputation was implemented on one percent of the missing data. Inferential statistics, specifically logistic regression, was used to determine the association between the admitting cHIS score with the risk of mortality and need of mechanical ventilation. Area under the receiver operating characteristic curve (AUROC) was used to assess the cHIS discrimination ability while Youden Index Analysis was used to determine the optimal cut-off values including the sensitivity and specificity of cHIS score. Following Mandrekar, an AUROC of at least 0.7 was acceptable.[22] To ensure robustness of the results, one-factor-at-a-time analysis by Czitrom was implemented.[23] Standard p-values were considered in the study, namely 0.1, 0.05, 0.01, and 0.001. The statistical software used was Stata.

## Ethical Considerations

The study adhered to the Principles of the Declaration of Helsinki and conducted following the Guidelines of the International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and the National Ethical Guidelines for Health and Health-Related Research (NEGHHRR).[24,25] The protocol and all relevant documents were reviewed and approved by the Institutional Ethics Review Committee. Individual information of patients remained strictly confidential. Patients were anonymized in the data collection form and only case numbers and code numbers were used. General data, clinical features, and laboratory results were abstracted from the hospital database and recorded. The investigators were responsible for the integrity of the data including its accuracy, completeness, legibility, originality, timeliness, and consistency. All study-related documents shall be kept and stored by the investigators for at least five years and will be discarded following prescribed measures.

## RESULTS

## Sociodemographic Profile of the Study Population

A total of 1,881 admitted patients that met the inclusion criteria was included in this study. A patient flow diagram is shown in Appendix B. Table 1 shows the sociodemographic profile of the study population.

Table 2 shows the frequency distribution of cHIS scores among the subjects. Patients with cHIS score of 0 comprised most of the population (29%), followed by those with a cHIS score of 1 (27.1%), cHIS score of 2 (18.6%), cHIS score of 3 (12.8%), cHIS score of 4 (7.5%), cHIS score of 5 (4%), and cHIS score of 6 (1%).

## Relationship between the cHIS Score and the Risk of Mortality

Table 3 shows the logistic regression of cHIS score and the risk mortality across the sociodemographic profile.

The cHIS score at admission regardless of value was a strong independent predictor of mortality and was internally consistent and robust across multiple sensitivity analyses. Higher cHIS scores correlated with higher risk of mortality. For instance, a cHIS score of 1 was associated with 2.7-fold

**Table 1.** Sociodemographic Profile of the Study Population (N = 1,881)

|  | Frequency | Percentage (%) |
|---|---|---|
| *Age* | | |
| Adult (19-44) | 452 | 24.0 |
| Middle Age (45-64) | 831 | 44.2 |
| Aged 65-80 | 526 | 28.0 |
| Aged >80 | 72 | 3.8 |
| *COVID-19 Severity* | | |
| Mild | 297 | 16.0 |
| Moderate | 401 | 21.6 |
| Severe | 663 | 35.7 |
| Critical | 497 | 26.7 |
| *Body Mass Index* | | |
| Underweight | 47 | 2.5 |
| Normal | 943 | 50.1 |
| Overweight | 605 | 32.2 |
| Obese | 286 | 15.2 |
| *Sex* | | |
| Male | 983 | 52.3 |
| Female | 898 | 47.7 |
| *Comorbidities* | | |
| Hypertension | 992 | 52.7 |
| Diabetes Mellitus | 734 | 39.0 |
| Chronic Kidney Disease | 412 | 21.9 |
| Cardiovascular Disease | 341 | 18.1 |
| Chronic Lung Disease | 273 | 14.5 |
| Neurologic Disease | 121 | 6.4 |
| Solid Cancers | 72 | 3.8 |
| Chronic Liver Disease | 52 | 2.8 |
| HIV-AIDS | 13 | 0.7 |
| Leukemias | 5 | 0.3 |
| Others | 140 | 7.4 |

**Table 2.** Frequency Distribution of cHIS Scores among COVID-19 Confirmed Patients

| cHIS Score | Frequency | Percentage (%) |
|---|---|---|
| 0 | 545 | 29.0 |
| 1 | 509 | 27.1 |
| 2 | 350 | 18.6 |
| 3 | 241 | 12.8 |
| 4 | 142 | 7.5 |
| 5 | 75 | 4.0 |
| 6 | 19 | 1.0 |
| *Total* | **1,881** | **100.0** |

**Table 3.** Table of Logistic Regression for cHIS Score and Risk of Mortality

| | Overall | cHIS ≥1 | cHIS ≥2 | cHIS ≥3 | cHIS ≥4 | cHIS ≥5 | cHIS = 6 |
|---|---|---|---|---|---|---|---|
| **COVID-19 Hyperinflammatory Score (cHIS Score)** | | | | | | | |
| Overall | -0.979***<br>(0.0850) | | | | | | |
| cHIS ≥1 | | -2.723***<br>(0.458) | | | | | |
| cHIS ≥2 | | | -2.117***<br>(0.228) | | | | |
| cHIS ≥3 | | | | -2.087***<br>(0.200) | | | |
| cHIS ≥4 | | | | | 2.236***<br>(0.270) | | |
| cHIS ≥5 | | | | | | -3.477***<br>(0.716) | |
| **Body Mass Index (Control: Normal BMI)** | | | | | | | |
| Underweight | -1.612***<br>(0.539) | -1.638***<br>(0.546) | -1.840***<br>(0.520) | -1.555***<br>(0.488) | -1.374***<br>(0.508) | -1.671***<br>(0.490) | -1.614***<br>(0.493) |
| Overweight | -0.0290 | -0.0468 | -0.0578 | -0.0145 | -0.0637 | -0.0819 | -0.0728 |
| Obese | -0.184 | -0.188 | -0.211 | -0.158 | -0.249 | -0.257 | -0.222 |
| **COVID-19 Severity (Control: Mild)** | | | | | | | |
| Moderate | 0.841* | 1.112** | 0.872* | 0.583 | 0.560 | 0.637 | 0.647 |
| Severe | 0.849** | 0.652* | 0.705* | 0.374 | 0.0809 | -0.0595 | -0.0568 |
| Critical | -2.982***<br>(0.385) | -3.579***<br>(0.362) | -3.348***<br>(0.377) | -3.690***<br>(0.363) | -4.099***<br>(0.355) | -4.274***<br>(0.348) | -4.411***<br>(0.344) |
| **Comorbidities[a]** | | | | | | | |
| Chronic Lung Disease | -0.591**<br>(0.253) | -0.544**<br>(0.247) | -0.504**<br>(0.245) | -0.601**<br>(0.247) | -0.489**<br>(0.243) | -0.554**<br>(0.241) | -0.520**<br>(0.239) |

*Standard errors (only shown for variables with significant and consistent correlation) in parentheses*
*Levels of significance: ***p<0.01, **p<0.05, *p<0.1*
*[a] Excludes comorbidities with nonsignificant correlation*

increased likelihood of mortality compared to controls, while a cHIS score of 5 was associated with 3.5-fold increased likelihood of mortality compared to controls.

Among the sociodemographic data, being underweight or having a BMI of less than 18.5 kg/m², and the presence of a chronic lung disease both significantly correlated with mortality at p<0.01 and p<0.05, respectively, regardless of cHIS scores.

A COVID-19 stratification of critical at admission was also a significant risk of mortality regardless of cHIS scores at p<0.01.

### Relationship between the cHIS Score and the Need of Mechanical Ventilation

Table 4 shows the logistic regression of cHIS score and the need of mechanical ventilation across the socio-demographic data.

The cHIS score at admission regardless of value was an independent predictor of the need for mechanical ventilation and was internally consistent and robust across multiple sensitivity analyses. For instance, a cHIS score of 3 was associated with 1.6-fold increased need of mechanical ventilation, even after controlling for age, sex, BMI, and severity.

A BMI of less than 18.5 kg/m², i.e., being underweight, and a stratification of critical both significantly correlated with the need of mechanical ventilation at p<0.01, regardless of cHIS scores, while no comorbidities were associated with increased need of mechanical ventilation.

### Optimal Cut-off Values of cHIS Score, Including its Sensitivity and Specificity

Table 5 shows the optimal cutoffs of cHIS score in predicting mortality and need of mechanical ventilation.

Using the Youden Index, it was determined that a cHIS score of ≥3 was predictive of mortality with a sensitivity of 88.59% and a specificity of 71.72%, while a cHIS score of ≥2 was predictive of the need of mechanical ventilation with a sensitivity of 84.02% and a specificity of 70.82%. These cHIS values provided the best tradeoff between sensitivity and specificity in predicting the two adverse outcomes. Moreover, the AUROC analysis validated that they were within the acceptable discrimination value of at least 0.70.[22] The actual tables for AUROC are presented in Appendices C and D.

### DISCUSSION

Even prior to SARS-CoV-2's explosion to pandemic level in early 2020, a mounting body of evidence has implicated

**Table 4.** Table of Logistic Regression for cHIS Score and Need of Mechanical Ventilation

|  | Overall | cHIS ≥1 | cHIS ≥2 | cHIS ≥3 | cHIS ≥4 | cHIS ≥5 | cHIS = 6 |
|---|---|---|---|---|---|---|---|
| **COVID-19 Hyperinflammatory Score (cHIS Score)** | | | | | | | |
| Overall | **0.586***** (0.0885) | | | | | | |
| cHIS ≥1 | | **1.249***** (0.330) | | | | | |
| cHIS ≥2 | | | **1.174***** (0.245) | | | | |
| cHIS ≥3 | | | | **1.563***** (0.247) | | | |
| cHIS ≥4 | | | | | **1.378***** (0.335) | | |
| cHIS ≥5 | | | | | | **1.887***** (0.690) | |
| **Body Mass Index (Control: Normal BMI)** | | | | | | | |
| Underweight | **1.336***** (0.517) | **1.541***** (0.502) | **1.509***** (0.499) | **1.324***** (0.498) | **1.354***** (0.492) | **1.556***** (0.477) | **1.530***** (0.479) |
| Overweight | -0.392 | -0.374 | -0.360 | -0.394 | -0.361 | -0.328 | -0.344 |
| Obese | -0.576 | -0.569* | -0.548 | -0.606* | -0.532 | -0.513 | -0.560* |
| **COVID-19 Severity (Control: Mild)** | | | | | | | |
| Moderate | -0.668 | -0.815* | -0.630 | -0.521 | -0.491 | -0.533 | -0.538 |
| Severe | -0.827** | -0.736* | -0.685* | -0.593 | -0.356 | -0.303 | -0.296 |
| Critical | **4.496***** (0.380) | **4.951***** (0.377) | **4.833***** (0.380) | **4.918***** (0.366) | **5.251***** (0.361) | **5.361***** (0.358) | **5.487***** (0.358) |

*Standard errors (only shown for variables with significant and consistent correlation) in parentheses*
*Levels of significance: \*\*\*p<0.01, \*\*p<0.05, \*p<0.1*

dysregulated inflammatory response as the culprit in severe COVID-19 disease.[2,3,4,12] This observation has sparked numerous attempts to quantify the degree of immune dysregulation by using a combination of clinical and laboratory parameters to predict clinical outcomes. Among these were the COVID-19-associated Hyperinflammation (COV-HI); neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR); and the Ventilation in COVID Estimator (VICE) and Death In COVID-19 Estimator (DICE).[26-28] Meanwhile, the cHIS score has been externally validated in at least two studies, but has never been applied to a Southeast-Asian population.[13,14] To the authors' best knowledge, this study is the largest external validation of the cHIS score with 1,881 subjects, and the first one in the country.

**Table 5.** Optimal Cutoff Values of cHIS Scores

| cHIS Score | Outcomes | | | |
|---|---|---|---|---|
| | Risk of Mortality | | Need of Mechanical Ventilation | |
| | Sensitivity | Specificity | Sensitivity | Specificity |
| *cHIS ≥1* | 100.00 | 0.00 | 0.00 | 100.00 |
| *cHIS ≥2* | 100.00 | 0.00 | **84.02** | **70.82** |
| *cHIS ≥3* | **88.59** | **71.72** | 64.50 | 89.08 |
| *cHIS ≥4* | 96.89 | 43.91 | 37.48 | 96.65 |
| *cHIS ≥5* | 99.79 | 20.92 | 17.55 | 99.62 |
| *cHIS = 6* | 100.00 | 0.00 | 0.00 | 100.00 |

The main objective of this study was to correlate the cHIS score among COVID-19 confirmed patients taken on admission and their risk of mortality and need of mechanical ventilation.

By regression analysis, the one-time cHIS score was found to be associated with mortality and need of mechanical ventilation, and was consistently robust across multiple sensitivity analyses. This was consistent with the three previous studies linking patient cHIS score to adverse clinical events.[12-14]

Noteworthy was the conservation of the relationship even when certain components of the cHIS score were excluded from analysis as they were not tested for all patients at the time of admission. Under the cHIS parameter of cytokinemia, we decided to omit serum triglyceride as it was not routinely taken as a non-fasting test on admission, and the IL-6 as it was not locally available. Thus, only CRP was the surrogate marker used for cytokinemia in this study.

Further analysis showed that cutoff cHIS scores of 3 and 2 can be used as a predictor of mortality and need of mechanical ventilation, respectively. This result was comparable to the original findings by Webb et al. which showed that a threshold score of 2 or more was predictive of both mortality (sensitivity 95%, specificity 59%) and mechanical ventilation (sensitivity 96%, specificity 49%).[12] Meanwhile, the validation study by Yildirim et al. demonstrated a cHIS score of 3 or more to be associated with ICU mortality (sensitivity 63%, specificity 50%) and invasive mechanical ventilation (sensitivity 61%, specificity 51%).[13] Among COVID-19 patients with

rheumatic diseases, Hsu et al. found that a cHIS score of 2 or more had higher odds of intensive care unit admission (OR 3.45 [95% CI 1.98–5.99]), mechanical ventilation (66.20 [8.98–487.80]), and in-hospital mortality (16.37 [4.75–56.38]) compared with those with a cHIS of less than 2.[14]

The strength of the cHIS score in predicting adverse outcomes stems from the theoretical robustness of its six components, which reflect physiologic features of archetypal hyperinflammatory states, such as HLH, MAS, and CRS.[12] Several studies had previously correlated the individual components of the cHIS score, namely fever;[29,30] macrophage activation;[31,32] hematologic dysfunction;[33-36] coagulopathy;[37] hepatic injury;[38-42] and cytokinemia,[43-47] to adverse clinical outcomes, but a composite of these clinical features had never been used as a triaging and prognostication tool up until Webb et al. came up with the said scoring system.

An interesting finding in this study was the association of underweight, but not obesity, with the risk of mortality and need of mechanical ventilation across all cHIS scores. Although obesity is more commonly linked to poor outcomes in COVID-19, some studies have in fact shown that being underweight, being associated with malnutrition, can be contributory to unfavorable clinical outcomes.[48-51] Since malnutrition is prevalent among COVID-19 patients, ranging from 27.5% to 82.6%, the European Society for Clinical Nutrition and Metabolism (ESPEN) has recommended providing an energy level of 27–30 kcal/kg body weight and a protein intake of more than one gram per kilogram body weight for COVID-19 patients.[52-57]

This study also showed that among the comorbidities, the presence of chronic lung disease was a significant independent predictor of mortality across all cHIS scores. Indeed, several studies have linked chronic lung disease to severe outcomes in COVID-19; the pathophysiologic explanation is that angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine-2 (TMPRSS2), which are cellular targets of SARS-CoV-2, are widely expressed in the lung tissue.[57-60] Since smoking significantly increases the expression of ACE2, patients with COPD are also shown to have increased expression of ACE2 in the airway epithelium, and thus adverse outcomes.[61]

A stratification of critical was also found to be associated with mortality and need of mechanical ventilation, regardless of cHIS score. However, this may be explained by the fact that COVID-19 critical patients were either already intubated or in shock at the outset, and thus would correlate cleanly with the said outcomes.

A limitation of this study was that COVID-19 variants with their differential virulence were not taken into account as potential independent variables affecting the risk of mortality and need of mechanical ventilation, as genomic testing was not available locally during the study period. By 2021, at least five variants of concern have been documented, including Alpha, Beta, Gamma, Delta, and Omicron.[62] Another potential confounder that could have strong impact on the patients' outcomes but was not included in the study, was their vaccination status. Before the year 2021 ended, the vaccination rollout was at 55% for those who received at least one dose and 44% for those fully vaccinated.[63] On top of these, our study being retrospective in nature, was limited by its vulnerability to recall bias, selection bias, and incomplete data.[64]

## CONCLUSION

Among COVID-19 patients, the cHIS score taken at admission correlated with the risk of mortality and the need for mechanical ventilation. With optimal sensitivities and specificities, a cut-off cHIS score of ≥2 can be used as a predictor of the need for mechanical ventilation while a cutoff cHIS score of ≥3 can be used as a predictor of mortality.

We recommend requesting the laboratory tests included in the cHIS scoring and applying the said score in the prognostication of all admitted COVID-19 patients. This cHIS scoring can be modified such that triglyceride and IL-6 can be safely omitted if these tests are not available. Prospective validation of the cHIS score should be the next direction of research in order to confirm these findings without the biases of a retrospective study. We also recommend considering the COVID-19 variant and the patient's vaccination status as independent variables in future studies.

In addition, regardless of cHIS scores, being underweight was predictive of mortality and need of mechanical ventilation, while the presence of chronic lung diseases was predictive of mortality. Thus, we strongly recommend SARS-CoV-2 vaccination among the underweight and those with chronic lung diseases in order to mitigate their higher risk for adverse outcomes compared to the general population.

# REFERENCES

1. COVID-19 cases | WHO COVID-19 dashboard [Internet]. 2022 [cited 2022 Jan]. Available from: https://data.who.int/dashboards/covid19/cases?m49=608&n=c

2. Eastin C, Eastin T. Clinical characteristics of Coronavirus Disease 2019 in China. J Emerg Med. 2020 Apr; 58(4):711–12. doi: 10.1016/j.jemermed.2020.04.004. PMCID: PMC7266766.

3. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020 Jul;72(7):1059-63. doi: 10.1002/art.41285. PMID: 32293098; PMCID: PMC7262347.

4. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 Jun:53:38-42. doi: 10.1016/j.cytogfr.2020.04.002. PMID: 32360420; PMCID: PMC7182527.

5. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9. PMID: 29907163; PMCID: PMC6003181.

6. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. doi: 10.1038/ni.3153. PMID: 25898198.

7. Hay KA, Hanafi L, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. PMID: 28924019; PMCID: PMC5701525.

8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. PMID: 31986264; PMCID: PMC7159299.

9. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015 Jun;26(3):263-80. doi: 10.1016/j.cytogfr.2014.10.001. PMID: 25466631.

10. Davì S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011 Apr;38(4):764-8. doi: 10.3899/jrheum.100996. PMID: 21285158.

11. Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019 Jan 31:10:55. doi: 10.3389/fimmu.2019.00055. PMID: 30766533; PMCID: PMC6365431.

12. Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2020 Dec;2(12):e754-e763. doi: 10.1016/S2665-9913(20)30343-X. PMID: 33015645; PMCID: PMC7524533.

13. Yildirim M, Halacli B, Yuce D, Gunegul Y, Ersoy EO, Topeli A. Assessment of admission COVID-19 associated hyperinflammation syndrome score in critically-ill COVID-19 patients. J Intensive Care Med. 2023 Jan;38(1):70-7. doi: 10.1177/08850666221131265. PMID: 36213939; PMCID: PMC9549159.

14. Hsu TY, D'Silva KM, Patel NJ, Wang J, Mueller AA, Fu X, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatol. 2021 Sep; 3(9): e638–e647. doi: 10.1016/S2665-9913(21)00140-5. PMID: 34095857; PMCID: PMC8163294.

15. Clinical management of COVID-19 - Interim Guidance [Internet]. Jun 2020 [cited 2022 Jan]. Available from: https://reliefweb.int/report/world/clinical-management-covid-19-interim-guidance-may-2020

16. Abad CL, Lansang MAD, Cordero CP, Viray EDE, Tiangco BJ, Bello JAG, et al. Early experience with COVID-19 patients in a private tertiary hospital in the Philippines: Implications on surge capacity, healthcare systems response, and clinical care. Clin Epidemiol Glob Health. 2021 Apr-Jun;10:100695. doi: 10.1016/j.cegh.2020.100695. PMID: 33490719; PMCID: PMC7813488.

17. Salva EP, Villarama JB, Lopez EB, Sayo AR, Villanueva AMG, Edwards T, et al. Epidemiological and clinical characteristics of patients with suspected COVID-19 admitted in Metro Manila, Philippines. Trop Med Health. 2020 Jun 22;48(1):51. doi: 10.1186/s41182-020-00241-8. PMID: 34686216; PMCID: PMC7306563.

18. Salamat MSS, Malundo AFG, Abad CLR, Sandejas JCM, Planta JEG, Poblete JB, et al. Characteristics and factors associated with mortality of 200 COVID-19 patients at a Philippine COVID-19 tertiary referral center. Acta Med Philipp. 2021Apr.2755(2):173-82. doi: 10.47895/amp.v55i2.2845.

19. Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146. PMID: 17695343.

20. Kastner M, Wilczynski NL, Walker-Dilks C, McKibbon K, Haynes B. Age-specific search strategies for Medline. J Med Internet Res. 2006 Oct 25;8(4):e25. doi: 10.2196/jmir.8.4.e25. PMID: 17213044; PMCID: PMC1794003.

21. Bassett J, International Diabetes Institute, World Health Organization Regional Office for the Western Pacific, International Association for the Study of Obesity, International Obesity TaskForce. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Australia: Health Communications Australia; 2000. pp. 17-18.

22. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010 Sep;5(9):1315-6. doi: 10.1097/JTO.0b013e3181ec173d. PMID: 20736804.

23. Czitrom V. One-Factor-at-a-Time versus Designed Experiments. Am Stat. 1999 May;53(2):126–31.

24. Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. 1998 Apr-Jun;6(2):65-74. doi:10.1080/105294199277860. PMID: 10386329.

25. Philippine Health Research Ethics Board – Ad Hoc Committee for Updating the National Ethical Guidelines. National Ethical Guidelines for Health and Health-Related Research [Internet]. 2017 [cited 2021 Dec]. Available from: https://ethics.healthresearch.ph/index.php/phoca-downloads/category/4-neg?download=98:neghhr-2017.

26. Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020 Oct;2(10):e594-e602. doi: 10.1016/S2665-9913(20)30275-7. PMID: 32864628; PMCID: PMC7442426.

27. Yang A, Liu J, Tao W, Li H. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020 Jul:84:106504. doi: 10.1016/j.intimp.2020.106504. PMID: 32304994; PMCID: PMC7152924.

28. Nicholson CJ, Wooster L, Sigurslid HH, Li RH, Jiang W, Tian W, et al. Estimating risk of mechanical ventilation and mortality among adult COVID-19 patients admitted to Mass General Brigham: the VICE and DICE scores. EClinicalMedicine. 2021 Mar:33:100765. doi: 10.1016/j.eclinm.2021.100765. PMID: 33655204; PMCID: PMC7906522.

29. Ding F, Feng Y, Han L, Zhou Y, Ji Y, Hao H, et al. Early fever is associated with clinical outcomes in patients with Coronavirus Disease. Front Public Health. 2021 Aug 26:9:712190. doi: 10.3389/fpubh.2021.712190. PMID: 34513787; PMCID: PMC8427156.

30. Ng DHL, Choy CY, Chan Y, Young BE, Fong S, Ng LFP, et al. Fever patterns, cytokine profiles and outcomes in COVID-19. Open Forum Infect Dis. 2020 Aug 24;7(9):ofaa375. doi: 10.1093/ofid/ofaa375. PMID: 32999893; PMCID: PMC7499767.

31. Lino K, Guimarães GMC, Alves LS, Oliveira AC, Faustino R, Fernandes CS, et al. Serum ferritin at admission in hospitalized COVID-19 patients as a predictor of mortality. Braz J Infect Dis. 2021 Mar-Apr;25(2):101569. doi: 10.1016/j.bjid.2021.101569. PMID: 33736948; PMCID: PMC7959266.

32. Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19.

33. Prozan L, Shusterman E, Ablin J, Mitelpunkt A, Weiss-Meilik A, Adler A, et al. Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection. Sci Rep. 2021 Nov 2;11(1):21519. doi: 10.1038/s41598-021-00927-x. PMID: 34728719; PMCID: PMC8563769.

34. Zeng Z, Feng S, Chen G, Wu J. Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: a prospective cohort study. BMC Infect Dis. 2021 Jan 18;21(1):80. doi: 10.1186/s12879-021-05796-3. PMID: 33461497; PMCID: PMC7812552.

35. Sarkar S, Khanna P, Singh AK. The impact of neutrophil-lymphocyte count ratio in COVID-19: a systematic review and meta-analysis. J Intensive Care Med. 2022 Jul;37(7):857-69. doi: 10.1177/08850666211045626. PMID: 34672824; PMCID: PMC9160638.

36. Asrie F, Tekle E, Gelaw Y, Dagnew M, Gelaw A, Negash M, et al. Baseline thrombocytopenia and disease severity among COVID-19 patients, Tibebe Ghion Specialized Hospital COVID-19 Treatment Center, Northwest Ethiopia. J Blood Med. 2022 Jun 10:13:315-25. doi: 10.2147/JBM.S366478. PMID: 35712680; PMCID: PMC9196661.

37. Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021 Aug 26;16(8):e0256744. doi: 10.1371/journal.pone.0256744. PMID: 34437642; PMCID: PMC8389366.

38. Szarpak L, Ruetzler K, Safiejko K, Hampel M, Pruc M, Kanczuga-Koda L, et al. Lactate dehydrogenase level as a COVID-19 severity marker. Am J Emerg Med. 2021 Jul;45:638–9. doi: 10.1016/j.ajem.2020.11.025. PMID: 33246860; PMCID: PMC7666711.

39. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med. 2020 Sep;38(9):1722-6. doi: 10.1016/j.ajem.2020.05.073. PMID: 32738466; PMCID: PMC7251362.

40. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. Preprint. bioRxiv. February 4, 2020. doi: doi: 10.1101/2020.02.03.931766.

41. Sultan S, Altayar O, Siddique S, Davitkov P, Feuerstein JD, Lim JK, et al. AGA Institute rapid review of the GI and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020 Jul;159(1):320-334.e27. doi: 10.1053/j.gastro.2020.05.001. PMID: 32407808; PMCID: PMC7212965.

42. Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020 Jul;72(1):287-304. doi: 10.1002/hep.31281. PMID: 32298473; PMCID: PMC7262242.

43. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis. 2020 Apr 29;7(5):ofaa153. doi: 10.1093/ofid/ofaa153. PMID: 32455147; PMCID: PMC7197542.

44. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 Jun:127:104370. doi: 10.1016/j.jcv.2020.104370. PMID: 32344321; PMCID: PMC7194648.

45. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4. doi: 10.1016/j.jaci.2020.05.008. PMID: 32425269; PMCID: PMC7233239.

46. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 15;19(1):18. doi: 10.1186/s12941-020-00362-2. PMID: 32414383; PMCID: PMC7227180.

47. Yitbarek GY, Walle Ayehu G, Asnakew S, Ayele FY, Gare MB, Mulu AT, et al. The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review. SAGE Open Med. 2021 Oct 11;9:20503121211050755. doi: 10.1177/20503121211050755. PMID: 34659766; PMCID: PMC8516378.

48. Singh R, Rathore SS, Khan H, Karale S, Chawla Y, Iqbal K, et al. Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression. Front Endocrinol (Lausanne). 2022 Jun 3;13:780872. doi: 10.3389/fendo.2022.780872. PMID: 35721716; PMCID: PMC9205425.

49. Kananen L, Eriksdotter M, Boström AM, Kivipelto M, Annetorp M, Metzner C, et al. Body mass index and Mini Nutritional Assessment-Short Form as predictors of in-geriatric hospital mortality in older adults with COVID-19. Clin Nutr. 2022 Dec;41(12):2973-9. doi: 10.1016/j.clnu.2021.07.025. PMID: 34389208; PMCID: PMC8318666.

50. Bouziotis J, Arvanitakis M, Preiser JC; ISARIC Clinical Characterisation Group. Association of body mass index with COVID-19 related in-hospital death. Clin Nutr. 2022 Dec;41(12):2924-6. doi: 10.1016/j.clnu.2022.01.017. PMID: 35123821; PMCID: PMC8800162.

51. Kim TS, Roslin M, Wang JJ, Kane J, Hirsch JS, Kim EJ, et al. BMI as a risk factor for clinical outcomes in patients hospitalized with COVID-19 in New York. Obesity (Silver Spring). 2021 Feb;29(2):279-84. doi: 10.1002/oby.23076. PMID: 33128848; PMCID: PMC8191573.

52. Bedock D, Bel Lassen P, Mathian A, Moreau P, Couffignal J, Ciangura C, et al. Prevalence and severity of malnutrition in hospitalized COVID-19 patients. Clin Nutr ESPEN. 2020 Dec;40:214-9. doi: 10.1016/j.clnesp.2020.09.018. PMID: 33183539; PMCID: PMC7500887.

53. Rouget A, Vardon-Bounes F, Lorber P, Vavasseur A, Marion O, Marcheix B, et al. Prevalence of malnutrition in coronavirus disease 19: the NUTRICOV study. Br J Nutr. 2021 Nov 14;126(9):1296-1303. doi: 10.1017/S0007114520005127. PMID: 33342449; PMCID: PMC7853739.

54. Liu A, Cong J, Wang Q, Mei Y, Peng Y, Zhou M, et al. Risk of malnutrition is common in patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: a cross-sectional study. J Nutr. 2021 Jun 1;151(6):1591-6. doi: 10.1093/jn/nxab009. PMID: 33693698; PMCID: PMC7989444.

55. Allard L, Ouedraogo E, Molleville J, Bihan H, Giroux-Leprieur B, Sutton A, et al. Malnutrition: percentage and association with prognosis in patients hospitalized for Coronavirus Disease 2019. Nutrients. 2020 Nov 28;12(12):3679. doi: 10.3390/nu12123679. PMID: 33260603; PMCID: PMC7761464.

56. Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020 Jun;39(6):1631-8. doi: 10.1016/j.clnu.2020.03.022. PMID: 32305181; PMCID: PMC7138149.

57. Ahrenfeldt LJ, Nielsen CR, Möller S, Christensen K, Lindahl-Jacobsen R. Burden and prevalence of risk factors for severe COVID-19 in the ageing European population - a SHARE-based analysis. Z Gesundh Wiss. 2022;30(9):2081-90. doi: 10.1007/s10389-021-01537-7. PMID: 33868899; PMCID: PMC8036158.

58. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020 May 14;55(5):2000547. doi: 10.1183/13993003.00547-2020. PMID: 32217650; PMCID: PMC7098485.

59. Hojo M, Terada-Hirashima J, Sugiyama H. COVID-19 and bronchial asthma: current perspectives. Glob Health Med. 2021 Apr 30;3(2):67–72. doi: 10.35772/ghm.2020.01117. PMID: 33937568; PMCID: PMC8071679.

60. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. PMID: 32142651; PMCID: PMC7102627.

61. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020 May 14;55(5):2000688. doi: 10.1183/13993003.00688-2020. PMID: 32269089; PMCID: PMC7144263.

62. Campos HJ, Raza MN, Arcede JP, Martinez JGT, Caga-anan RL. Vaccination and variants: a COVID-19 multi-strain model evolution for the Philippines. Front Appl Math Stat. 2023;9:1029018. doi: 10.3389/fams.2023.1029018.

63. COVID-19 Vaccination Dashboard, Department of Health Philippines [Internet]. 2022 [cited 2022 Aug]. Available from: https://web.archive.org/web/20220815074743/https://doh.gov.ph/

64. Talari K, Goyal M. Retrospective studies - utility and caveats. J R Coll Physicians Edinb. 2020 Dec;50(4):398-402. doi: 10.4997/JRCPE.2020.409. PMID: 33469615.

# APPENDICES

**Appendix A.** The six components of the COVID-19-associated hyperinflammatory syndrome (cHIS) criteria and the parameters used to score them

| cHIS Parameters | Operational Definition |
|---|---|
| *Fever* | Temperature of >38.0°C |
| *Macrophage Activation* | Ferritin of ≥700 µg/L |
| *Hematologic Dysfunction* | Neutrophil-to-lymphocyte ratio of ≥10, OR Both hemoglobin of ≤9.2 g/dL, AND platelet count of ≤110×10⁹ cells/L |
| *Coagulopathy* | D-dimer of ≥1.5 µg/mL |
| *Hepatic Injury* | Lactate dehydrogenase of ≥400 U/L, OR Aspartate aminotransferase of ≥100 U/L |
| *Cytokinemia* | C-reactive protein of ≥15 mg/dL, OR Triglyceride of ≥150 mg/dL[a], OR Interleukin-6 of ≥15 pg/mL[b] |

[a] *Excluded as a parameter as it is not routinely taken as a non-fasting lab at SPMC*

[b] *Excluded as a parameter as it was not available at SPMC during the study period*



**Appendix B.** Flow diagram of the study participants.

Area under ROC curve = 0.6795

**A. cHIS ≥1**

Area under ROC curve = 0.8017

**B. cHIS ≥2**

Area under ROC curve = 0.8016

**C. cHIS ≥3**

Area under ROC curve = 0.7040

**D. cHIS ≥4**

Area under ROC curve = 0.6036

**E. cHIS ≥5**

Area under ROC curve = 0.5000

**F. cHIS = 6**

**Appendix C.** AUROC analysis per cHIS cutoff score for mortality outcome.

**Appendix D.** AUROC analysis per cHIS cutoff score for need of mechanical ventilation outcome.